Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Accumulated Expenses (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Accumulated Expenses for 4 consecutive years, with $35.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 30.48% to $35.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.4 million through Dec 2025, down 30.48% year-over-year, with the annual reading at $35.4 million for FY2025, 30.48% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $35.4 million at Centessa Pharmaceuticals, up from $20.4 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $50.9 million in Q4 2024, with the low at $15.3 million in Q1 2023.
  • Average Accumulated Expenses over 4 years is $24.8 million, with a median of $23.4 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses soared 84.46% in 2024, then crashed 30.48% in 2025.
  • Over 4 years, Accumulated Expenses stood at $24.5 million in 2022, then grew by 12.52% to $27.6 million in 2023, then skyrocketed by 84.46% to $50.9 million in 2024, then plummeted by 30.48% to $35.4 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $35.4 million, $20.4 million, and $24.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.